放射治疗相关综合治疗在肝细胞癌中的应用研究进展

摘要/Abstract

摘要： 肝细胞癌（hepatocellular carcinoma,HCC）是最常见的原发性肝脏恶性肿瘤,多数患者就诊时处于进展期肝癌,生存预后较差。随着新技术及药物治疗的发展,放射治疗、化学药物治疗、靶向和免疫药物在HCC治疗中的应用价值得到重视,尤其对于无手术切除机会的患者尤其重要,与经导管动脉化疗栓塞术联合有望成为HCC治疗的新选择。不能手术的小肝癌或早期肝癌,立体定向放射治疗已经成为根治性手段之一。此外,放射治疗通过释放肿瘤抗原可以提升免疫治疗的效果,二者具有协同增效作用,在不可手术的晚期HCC,放射治疗与靶向、免疫治疗联合在许多临床试验中已取得令人瞩目的效果,并且是安全可控的。本文主要对放射治疗联合药物治疗HCC的最新研究进展进行综述,为当前原发性肝癌特别是进展期肝癌的临床治疗提供更多的联合治疗参考及临床研究探索方向。

关键词: 肝细胞癌, 放射治疗, 靶向治疗, 免疫治疗

Abstract: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, and most patients present with advanced liver cancer and a poor survival prognosis. With the development of new technologies and drug therapies, the value of radiotherapy, chemotherapy, targeted and immune drugs in HCC has been valued, especially for patients without surgical resection opportunities, and combination with hepatic artery chemoembolization is expected to become a new treatment option for HCC. For inoperable small liver cancer or early liver cancer, stereotactic radiation therapy has become one of the radical means. In addition, radiotherapy can promote the effect of immunotherapy by releasing tumor antigens, the two have a synergistic effect, in the inoperable late HCC radiotherapy combined with targeted, immunotherapy has achieved remarkable results in many clinical trials, and is safe and controllable. This paper mainly summarizes the latest research progress of radiotherapy combined drug therapy in HCC, and provides more combination treatment references and clinical research exploration directions for the current clinical treatment of primary liver cancer, especially advanced liver cancer.

Key words: Hepatocellular carcinoma, Radiotherapy, Targeted therapy, Immunotherapy

尹丽, 郭文杰, 袁芳琴, 徐清宇, 姚成云, 何侠. 放射治疗相关综合治疗在肝细胞癌中的应用研究进展[J]. 肝癌电子杂志, 2023, 10(4): 60-67.

Yin Li, Guo Wenjie, Yuan Fangqin, Xu Qingyu, Yao Chengyun, He Xia. Research progress of radiotherapy-based comprehensive therapy in primary hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2023, 10(4): 60-67.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] FORNER A, REIG M, BRUIX J.Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
[3] WIGG A J, PALUMBO K, WIGG D R.Radiotherapy for hepatocellular carcinoma: Systematic review of radiobiology and modeling projections indicate reconsideration of its use[J]. J Gastroenterol Hepatol, 2010, 25(4): 664-671.
[4] KOAY E J, OWEN D, DAS P.Radiation-Induced Liver Disease and Modern Radiotherapy[J]. Semin Radiat Oncol, 2018, 28(4): 321-331.
[5] KIM J, JUNG Y.Radiation-induced liver disease: current understanding and future perspectives[J]. Exp Mol Med, 2017, 49(7): e359.
[6] LEE J, SHIN I S, YOON W S, et al.Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review[J]. Radiother Oncol, 2020, 145: 63-70.
[7] SHEN P C, CHANG W C, LO C H, et al.Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma[J]. Int J Radiat Oncol Biol Phys, 2019, 105(2): 307-318.
[8] SAPIR E, TAO Y B, SCHIPPER M J, et al.Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018, 100(1): 122-130.
[9] KUDO M, KAWAMURA Y, HASEGAWA K, et al.Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update[J]. Liver Cancer, 2021, 10(3): 181-223.
[10] SHIINA S, GANI R A, YOKOSUKA O, et al.APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19[J]. Hepatol Int, 2020, 14(6): 920-929.
[11] ZENG Z C, TANG Z Y, JIA F, et al.A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma[J]. Cancer J, 2004, 10(5): 307-316.
[12] MENG M B, CUI Y L, LU Y, et al.Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis[J]. Radiother Oncol, 2009, 92(2): 184-194.
[13] WANG T H, HUANG P I, HU Y W, et al.Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry[J]. PLoS One, 2018, 13(1): e0190098.
[14] WU F X, LU H R, ZHU S L, et al.Efficacy of three-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus[J]. Onco Targets Ther, 2016, 9: 7141-7147.
[15] ZHANG T, ZHAO Y T, WANG Z, et al.Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma[J]. Medicine (Baltimore), 2016, 95(21): e3789.
[16] QIU H, MORAVAN M J, MILANO M T, et al.SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center[J]. J Gastrointest Cancer, 2018, 49(4): 463-469.
[17] KIMURA T, AIKATA H, DOI Y, et al. Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies[J]. Technol Cancer Res Treat, 2018, 17: 1533033818783450.
[18] LI X L, GUO W X, HONG X D, et al.Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis[J]. Hepatol Res, 2016, 46(11): 1088-1098.
[19] CHENG A L, KANG Y K, CHEN Z D, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[20] KUDO M, FINN R S, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[21] MARINO D, ZICHI C, AUDISIO M, et al.Second-line treatment options in hepatocellular carcinoma[J]. Drugs Context, 2019, 8: 212577.
[22] CHEN J, HE K, HAN Y, et al.Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Ann Hepatol, 2022, 27(4): 100710.
[23] CHANG W I, KIM B H, KIM Y J, et al.Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib[J]. J Gastroenterol Hepatol, 2022, 37(2): 387-394.
[24] BRADE A M, NG S, BRIERLEY J, et al.Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma[J]. Int J Radiat Oncol Biol Phys, 2016, 94(3): 580-587.
[25] WANG H, ZHU X, ZHAO Y, et al.Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma[J]. BMC Cancer, 2022, 22(1): 771.
[26] ZHOU J, WANG W, LI Q.Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages[J]. J Exp Clin Cancer Res, 2021, 40(1): 73.
[27] GAO Q, WANG X Y, QIU S J, et al.Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J]. Clin Cancer Res, 2009, 15(3): 971-979.
[28] SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al.Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features[J]. Gastroenterology, 2017, 153(3): 812-826.
[29] LLOVET J M, CASTET F, HEIKENWALDER M, et al.Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19(3): 151-172.
[30] EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
[31] DEMIR T, LEE S S, KASEB A O.Systemic therapy of liver cancer[J]. Adv Cancer Res, 2021, 149: 257-294.
[32] YAU T, PARK J W, FINN R S, et al.CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol, 2019, 30(Suppl 5): 874-875.
[33] ZHU A X, FINN R S, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952.
[34] KUDO M.Pembrolizumab for the Treatment of Hepatocellular Carcinoma[J]. Liver Cancer, 2019, 8(3): 143-154.
[35] QIN S, KUDO M, MEYER T, et al.Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2023: e234003.
[36] ABOU-ALFA G K, CHAN S L, FURUSE J, et al. A randomized, multicenter phase 3 study of durvalumab (D) andtremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study[J]. J Clin Oncol, 2018, 36 (15 Suppl): TPS4144.
[37] SHIGETA K, DATTA M, HATO T, et al.Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma[J]. Hepatology, 2020, 71(4): 1247-1261.
[38] LEE M S, RYOO B Y, HSU C H, et al.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21(6): 808-820.
[39] FINN R S, QIN S, IKEDA M, et al.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[40] GALLE P R, FINN R S, QIN S, et al.Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(7): 991-1001.
[41] CASAK S J, DONOGHUE M, FASHOYIN-AJE L, et al.FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma[J]. Clin Cancer Res, 2021, 27(7): 1836-1841.
[42] CHEUNG T T, MA K W, SHE W H.A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis[J]. Hepatobiliary Surg Nutr, 2021, 10(2): 193-209.
[43] ESAGIAN S M, KAKOS C D, GIORGAKIS E, et al.Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J]. Cancers (Basel), 2021, 13(12): 2984.
[44] CHEN L C, LIN H Y, HUNG S K, et al.Role of modern radiotherapy in managing patients with hepatocellular carcinoma[J]. World J Gastroenterol, 2021, 27(20): 2434-2457.
[45] GALLUZZI L, BUQUÉ A, KEPP O, et al.Immunogenic cell death in cancer and infectious disease[J]. Nat Rev Immunol, 2017, 17(2): 97-111.
[46] RODRIGUEZ-RUIZ M E, RODRIGUEZ I, LEAMAN O, et al. Immune mechanisms mediating abscopal effects in radioimmunotherapy[J]. Pharmacol Ther, 2019, 196: 195-203.
[47] CYTLAK U M, DYER D P, HONEYCHURCH J, et al.Immunomodulation by radiotherapy in tumour control and normal tissue toxicity[J]. Nat Rev Immunol, 2022, 22(2): 124-138.
[48] NGWA W, IRABOR O C, SCHOENFELD J D, et al.Using immunotherapy to boost the abscopal effect[J]. Nat Rev Cancer, 2018, 18(5): 313-322.
[49] CHIANG C L, CHAN A C Y, CHIU K W H, et al. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy[J]. Front Oncol, 2019, 9: 1157.
[50] LI J X, DENG W X, HUANG S T, et al.Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study[J]. Radiat Oncol, 2022, 17(1): 106.
[51] CHINO F, STEPHENS SJ, CHOI SS, et al.The role of external beam radiotherapy in the treatment of hepatocellular cancer[J]. Cancer, 2018, 124(17): 3476-3489.
[52] ZHANG H, YANG A, ZHANG J.Efficacy of transcatheter arterial chemoembolization combined with ¹²⁵I seed implantation and three-dimensional conformal radiotherapy in advanced primary hepatocellular carcinoma[J]. J BUON, 2020, 25(2): 952-958.
[53] GAO F L, WANG Y, HUANG X Z, et al.I-125 seeds brachytherapy with transcatheter arterial chemoembolization for subcapsular hepatocellular carcinoma[J]. BMC Gastroenterol, 2022, 22(1): 273.
[54] WANG W, WANG C, SHEN J, et al.Integrated I-125 Seed Implantation Combined with Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus[J]. Cardiovasc Intervent Radiol, 2021, 44(10): 1570-1578.
[55] CHEN K, CHEN G, WANG H, et al.Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial[J]. J Hepatol, 2014, 61(6): 1304-1311.
[56] LI S, HE X, DANG L, et al.Efficacy of ¹²⁵I Versus Non-¹²⁵I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice[J]. Dig Dis Sci, 2018, 63(2): 321-328.
[57] MARRERO J A, KULIK L M, SIRLIN C B, et al.Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-750.
[58] OMATA M, CHENG A L, KOKUDO N, et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370.
[59] VILGRAIN V, PEREIRA H, ASSENAT E, et al.Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1624-1636.
[60] CHOW P K H, GANDHI M, TAN S B, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma[J]. J Clin Oncol, 2018, 36(19): 1913-1921.
[61] TAI W M D, LOKE K S H, GOGNA A, et al. A phaseⅡ open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678[J]. J Clin Oncol, 2020, 38(15 Suppl): 4590.
[62] BRUIX J, REIG M, SHERMAN M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853.
[63] RIAZ A, KULIK L, LEWANDOWSKI R J, et al.Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres[J]. Hepatology, 2009, 49(4): 1185-1193.
[64] MOLVAR C, LEWANDOWSKI R.Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts[J]. Semin Intervent Radiol, 2015, 32(4): 388-397.
[65] WANG N, HUANG A, KUANG B, et al.Progress in Radiotherapy for Cholangiocarcinoma[J]. Front Oncol, 2022, 12: 868034